TRPV4-P2X Receptor Crosstalk in Cough Hypersensitivity: Mechanistic Insights from Guinea Pig Models

Study Background and Research Question

Chronic cough, particularly refractory chronic cough (RCC), presents a substantial clinical burden, affecting up to 42% of patients with persistent symptoms of unknown origin or limited treatment response. Most RCC cases are characterized by cough hypersensitivity syndrome (CHS), yet the molecular mechanisms underlying this heightened sensitivity remain insufficiently explored. Two receptor families—Transient Receptor Potential Vanilloid Subtype 4 (TRPV4) and Adenosine Triphosphate (ATP)-gated Purinergic 2 (P2X) receptors—have independently been implicated in cough reflex modulation. However, the nature of their interaction, and the consequences for peripheral airway sensory neuron activation, have not been systematically examined in preclinical models. The reference study (Li et al., 2025) was designed to clarify the interplay between TRPV4 and P2X signaling in the context of cough hypersensitivity.

Key Innovation from the Reference Study

The central innovation of this research is the demonstration that TRPV4 activation amplifies the ATP-P2X signaling axis, driving sensory neuron hyperexcitability and cough hypersensitivity in guinea pig models. The work establishes not only that both TRPV4 and P2X3/4/7 receptors are upregulated during chronic cough, but also that TRPV4 modulation directly regulates ATP release and P2X receptor-mediated currents. This integrated approach uniquely connects upstream TRPV4 activation with downstream effector pathways that shape cough sensitivity phenotypes (Li et al., 2025).

Methods and Experimental Design Insights

• Model establishment: The authors employed a citric acid-induced cough hypersensitivity model in guinea pigs, leveraging both pharmacological agonists (GSK1016790A for TRPV4) and antagonists (HC067047 for TRPV4; A317491, PSB12062, and A804598 for P2X3/4/7) to dissect component contributions.
• Quantitative cough assessment: Cough frequency was objectively quantified post-stimulation, providing a behavioral readout of hypersensitivity.
• ATP and inflammatory marker quantification: Enzyme-linked immunosorbent assays (ELISAs) were used to measure ATP, substance P (SP), and calcitonin gene-related peptide (CGRP) in bronchoalveolar lavage, linking receptor activity to inflammatory and purinergic signaling outputs.
• Protein expression analysis: Western blotting and immunohistochemistry (IHC) were performed on tracheal carina and vagal ganglia tissues to determine relative levels of TRPV4 and P2X receptors. The use of Affinity-Purified Goat Anti-Mouse IgG (H+L), HRP Conjugated secondary antibodies in these workflows enabled robust detection of mouse-derived primary antibodies, providing high sensitivity and specificity for target proteins.
• Electrophysiological and calcium imaging studies: Vagal ganglion neurons were isolated and subjected to whole-cell patch clamp and calcium imaging to directly measure ATP-evoked inward currents and calcium fluxes, respectively.

Protocol Parameters

• TRPV4 agonist administration: GSK1016790A administered to model animals to activate TRPV4 prior to cough challenge.
• TRPV4 antagonist dosing: HC067047 used in both prevention and intervention modes to inhibit TRPV4-mediated signaling.
• P2X receptor blockade: A317491 (P2X3), PSB12062 (P2X4), and A804598 (P2X7) administered to assess receptor-specific roles in ATP-evoked responses.
• Immunodetection: Mouse primary antibodies targeting TRPV4 and P2X3/4/7, detected using HRP-conjugated secondary antibodies, followed by chemiluminescent or chromogenic substrate development as detailed in referenced protocols (protocol setup and QC guide).
• ELISA sample collection: Bronchoalveolar lavage fluid sampled post-intervention for ATP, SP, and CGRP quantification by ELISA.

Core Findings and Why They Matter

The study’s results provide compelling evidence that:

• TRPV4 activation (by GSK1016790A) increases cough frequency, while TRPV4 inhibition (HC067047) or P2X3/4/7 antagonism reduces coughs in sensitized animals.
• Both TRPV4 and P2X3/4/7 receptor expression are upregulated in tracheal carina and vagal ganglia in the chronic cough model, and this is reversible with TRPV4 blockade.
• TRPV4 activation elevates ATP release into the airway, which in turn stimulates P2X receptors on sensory neurons, enhancing ATP-evoked inward currents and calcium influx—key drivers of sensory neuron excitability and cough reflex amplification (Li et al., 2025).
• Inhibiting TRPV4 and/or P2X receptors reduces not only electrophysiological hyperexcitability but also the release of neuropeptides (SP, CGRP) associated with neurogenic inflammation, indicating a broad role in cough pathophysiology.

Collectively, these findings establish a direct mechanistic link between epithelial TRPV4 activation, ATP-mediated P2X receptor stimulation, and peripheral nerve sensitization—offering new targets for intervention in chronic cough states.

Comparison with Existing Internal Articles

Recent internal literature, such as Redefining Immunodetection: Mechanistic Precision and Strategy, highlights the pivotal role of Affinity-Purified Goat Anti-Mouse IgG (H+L), HRP Conjugated secondary antibodies in achieving robust signal amplification and reproducibility in immunodetection workflows. The reference study’s reliance on sensitive and specific immunoassays for receptor quantification underscores the ongoing relevance of HRP-conjugated secondary antibodies in translational research. Protocol-driven guidance from HRP Goat Anti-Mouse IgG (H+L) Antibody: Protocol Setup & QC Guide provides additional context for integrating these reagents into Western blot and IHC workflows, ensuring optimal antibody-antigen detection, especially in studies requiring quantification of low-abundance targets.

Furthermore, insights from Mechanism & Benchmarks confirm the importance of affinity purification and HRP conjugation for achieving low background and strong signal-to-noise ratios, as demonstrated in the receptor expression analyses of the reference study.

Limitations and Transferability

While the study robustly links TRPV4 and P2X receptor signaling to cough hypersensitivity in guinea pigs, there are notable limitations:

• Species specificity: Guinea pig airway neurobiology approximates human cough reflex physiology but may not fully recapitulate all aspects of human CHS or RCC.
• Chronicity and etiology: The citric acid model mimics certain features of chronic cough but may not reflect all clinical subtypes, particularly those with non-inflammatory or idiopathic origins.
• Pharmacological specificity: Although selective agonists/antagonists were used, potential off-target effects and pharmacokinetic differences between species can limit direct translational inference.
• Assay sensitivity: The success of immunodetection and ELISA-based quantification relies on the performance of secondary antibodies. Literature and product guidelines (see APExBIO product information) emphasize the need for strict protocol adherence, particularly for HRP conjugated antibody storage and use.

Thus, while the study lays a mechanistic foundation, further validation in clinical samples and human tissues is warranted.

Research Support Resources

Researchers aiming to study receptor-mediated signal amplification in immunoassays can leverage validated reagents such as the HRP Goat Anti-Mouse IgG (H+L) Antibody (SKU K1221) from APExBIO. This affinity-purified, horseradish peroxidase conjugated secondary antibody offers high specificity for mouse IgG and is suitable for Western blot, ELISA, immunohistochemistry, and related applications, facilitating sensitive detection of target proteins in translational research workflows. Proper storage at 4°C short-term or -20°C long-term, as recommended, ensures reagent stability and reproducible assay performance. Integrating such tools supports the rigorous quantification and reproducibility required for mechanistic studies of receptor signaling in airway and neuroimmune research.